ABSTRACT & COMMENTARY

Can a Blood-Based Test Serve as a Biomarker for Parkinson’s Disease?

March 15, 2023

The authors of this proof-of-concept study proposed that a noninvasive assay detecting pathology-associated α-synuclein extracted from blood may reveal a reliable biomarker for Parkinson’s disease.

Issue Date: March 15, 2023

Table of Contents

Dr. Stephen Brunton, physician editor, reports he is on the speakers bureau for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi; is a retained consultant for AstraZeneca, Novo Nordisk, and Sanofi; and is a stockholder with Paracrine. The relevant financial relationships listed have been mitigated. None of the remaining planners or authors for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements